Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INCCPIX · Entity 6757 | Vice Pres Organizational Dev | March 18, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUMBERLAND PHARMACEUTICALS INC
Report date March 18, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 · Expires 2036-03-18 | Direct | 21,000 |
Reported balance
After 2026-03-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 3,000 · Balance 21,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 20, 2026 21:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantOptions (right to buy) · Derivative | 3,000 | $2.80 Strike: $2.80 | $8,400.00 |
DisclosureSEC source: 0001087294-26-000035 · wk-form4_1774041673.xml · derivative · entry 1 Anthony Todd M. · CIK 0001969711 · Vice Pres Organizational Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 3,000 shares Expires 2036-03-18 Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:10 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantOptions (right to buy) · Derivative | 3,000 | $5.17 Strike: $5.17 | $15,510.00 |
DisclosureSEC source: 0001628280-25-013527 · wk-form4_1742332195.xml · derivative · entry 1 Anthony Todd M. · CIK 0001969711 · Vice Pres Organizational Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 3,000 shares Expires 2035-03-17 Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 00:24 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantOptions (right to buy) · Derivative | 3,000 | $1.71 Strike: $1.71 | $5,130.00 |
DisclosureSEC source: 0001214659-24-005211 · marketforms-65388.xml · derivative · entry 2 Anthony Todd M. · CIK 0001969711 · Vice Pres Organizational Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 3,000 shares Expires 2034-03-25 Read SEC document |
| March 23, 2024 Filed Mar 27, 2024 00:24 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 816 | $1.81 | $1,476.96 |
DisclosureSEC source: 0001214659-24-005211 · marketforms-65388.xml · nonDerivative · entry 1 Anthony Todd M. · CIK 0001969711 · Vice Pres Organizational Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,328 Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 21:50 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantOptions (right to buy) · Derivative | 3,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001209191-23-021288 · doc4.xml · derivative · entry 1 Anthony Todd M. · CIK 0001969711 · Vice Pres Organizational Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 3,000 shares Expires 2033-03-24 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.